STBT5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
Richard.Glen (talk | contribs) m Formatted Author Names |
No edit summary |
||
| (22 intermediate revisions by 2 users not shown) | |||
| Line 229: | Line 229: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/8/2025 | ||
| | |Katie Schieffer | ||
| | |12/8/2025 | ||
| | |Minimal genetic content added | ||
|- | |- | ||
|[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]] | |[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]] | ||
| Line 251: | Line 251: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/16/2025 | ||
| | |Katie Schieffer | ||
| | |10/16/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Elastofibroma|Elastofibroma]] | |[[STBT5:Elastofibroma|Elastofibroma]] | ||
| Line 297: | Line 297: | ||
|Katie Schieffer | |Katie Schieffer | ||
|9/22/2025 | |9/22/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Juvenile_hyaline_fibromatosis|Juvenile hyaline fibromatosis]] | |[[STBT5:Juvenile_hyaline_fibromatosis|Juvenile hyaline fibromatosis]] | ||
| Line 315: | Line 315: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/16/2025 | ||
| | |Katie Schieffer | ||
| | |10/16/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Fibroma_of_tendon_sheath|Fibroma of tendon sheath]] | |[[STBT5:Fibroma_of_tendon_sheath|Fibroma of tendon sheath]] | ||
| Line 381: | Line 381: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/21/2025 | ||
| | |Katie Schieffer | ||
| | |10/21/2025 | ||
| | | | ||
|- | |- | ||
| Line 423: | Line 423: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/8/2025 | ||
| | |Katie Schieffer | ||
| | |12/8/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]] | |[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]] | ||
| Line 453: | Line 453: | ||
|[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]] | |[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]] | ||
|Disease | |Disease | ||
| | |Kati | ||
e Schieffer | |||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |Minimal genetic content added | ||
|- | |- | ||
|[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]] | |[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]] | ||
| Line 521: | Line 522: | ||
|9/24/2025 | |9/24/2025 | ||
|12/24/2025 | |12/24/2025 | ||
| | |COMPLETE | ||
| | |12/18/2025 | ||
| | |Katie Schieffer | ||
| | |12/18/2025 | ||
| | | | ||
|- | |- | ||
| Line 543: | Line 544: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/10/2025 | ||
| | |Katie Schieffer | ||
| | |12/10/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]] | |[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]] | ||
| Line 562: | Line 563: | ||
|[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]] | |[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]] | ||
|Disease | |Disease | ||
|Mokhtar Abdelhammed, MD (trainee); | |||
Katie Schieffer (mentor) | |||
|3/1/2026 | |||
|6/30/2026 | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]] | |[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]] | ||
|Disease | |Disease | ||
| Line 662: | Line 664: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/8/2025 | ||
| | |Katie Schieffer | ||
| | |12/8/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]] | |[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]] | ||
| Line 673: | Line 675: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/10/2025 | ||
| | |Katie Schieffer | ||
| | |12/10/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Synovial_haemangioma|Synovial haemangioma]] | |[[STBT5:Synovial_haemangioma|Synovial haemangioma]] | ||
| Line 684: | Line 686: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |11/10/2025 | ||
| | |Katie Schieffer | ||
| | |11/10/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Intramuscular_angioma|Intramuscular angioma]] | |[[STBT5:Intramuscular_angioma|Intramuscular angioma]] | ||
| Line 695: | Line 697: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/10/2025 | ||
| | |Katie Schieffer | ||
| | |12/10/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]] | |[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]] | ||
| Line 717: | Line 719: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/10/2025 | ||
| | |Katie Schieffer | ||
| | |12/10/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]] | |[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]] | ||
| Line 781: | Line 783: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/11/2025 | ||
| | |Katie Schieffer | ||
| | |12/11/2025 | ||
| | |Minimal genetic content added | ||
|- | |- | ||
|[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]] | |[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]] | ||
| Line 792: | Line 794: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/11/2025 | ||
| | |Katie Schieffer | ||
| | |12/11/2025 | ||
| | |Minimal genetic content added | ||
|- | |- | ||
|[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]] | |[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]] | ||
| Line 911: | Line 913: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]] | |[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]] | ||
| Line 1,096: | Line 1,098: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/11/2025 | ||
| | |Katie Schieffer | ||
| | |12/11/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|- | |- | ||
| Line 1,116: | Line 1,118: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/11/2025 | ||
| | |Katie Schieffer | ||
| | |12/11/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]] | |[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]] | ||
| Line 1,131: | Line 1,133: | ||
| | | | ||
| | | | ||
| | |Consider linking to CNS tumor book | ||
|- | |- | ||
|[[STBT5:Benign_triton_tumour_/_neuromuscular_choristoma|Benign triton tumour / neuromuscular choristoma]] | |[[STBT5:Benign_triton_tumour_/_neuromuscular_choristoma|Benign triton tumour / neuromuscular choristoma]] | ||
| Line 1,191: | Line 1,193: | ||
|Disease | |Disease | ||
|Katie Schieffer | |Katie Schieffer | ||
| | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]] | |[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]] | ||
| Line 1,265: | Line 1,267: | ||
|[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]] | |[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]] | ||
|Disease | |Disease | ||
|Mokhtar Abdelhammed, MD | |Mokhtar Abdelhammed, MD (trainee); | ||
Katie Schieffer (mentor) | |||
|9/11/2025 | |9/11/2025 | ||
|12/11/2025 | |12/11/2025 | ||
| | |COMPLETE | ||
| | |12/29/2026 | ||
|Katie Schieffer | |Katie Schieffer | ||
| | |1/7/2026 | ||
| | | | ||
|- | |- | ||
|[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]] | |[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]] | ||
|Disease | |Disease | ||
| | |Mokhtar Abdelhammed, MD (trainee); | ||
| | Katie Schieffer (mentor) | ||
| | |3/1/2026 | ||
| | |6/30/2026 | ||
|PENDING | |||
| | | | ||
| | | | ||
| Line 1,331: | Line 1,335: | ||
|[[STBT5:Alveolar_soft_part_sarcoma|Alveolar soft part sarcoma]] | |[[STBT5:Alveolar_soft_part_sarcoma|Alveolar soft part sarcoma]] | ||
|Disease | |Disease | ||
| | |Maxine Sutcliffe, PhD | ||
| | |10/13/2025 | ||
| | |12/31/2025 | ||
| | |COMPLETE | ||
| | |12/24/2025 | ||
| | |Katie Schieffer | ||
| | |12/24/2025 | ||
| | | | ||
|- | |- | ||
| Line 1,373: | Line 1,377: | ||
|[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]] | |[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]] | ||
|Disease | |Disease | ||
| | |Maxine Sutcliffe, PhD | ||
| | |1/12/2026 | ||
| | |4/12/2026 | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,449: | Line 1,453: | ||
|[[STBT5:Ewing_sarcoma|Ewing sarcoma]] | |[[STBT5:Ewing_sarcoma|Ewing sarcoma]] | ||
|Disease | |Disease | ||
|Sadeem Qdaisat | |Sadeem Qdaisat (trainee); Eric McGinnis (mentor) | ||
|10/1/ | |10/1/2023 | ||
|12/9/2025 | |12/9/2025 | ||
|PENDING | |PENDING | ||
| | | | ||
| | |Katie Schieffer | ||
| | |||
| | | | ||
|- | |- | ||
|[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]] | |[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]] | ||
| Line 1,526: | Line 1,530: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |12/12/2025 | ||
| | |Katie Schieffer | ||
| | |12/12/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]] | |[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]] | ||
| Line 1,537: | Line 1,541: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
|12/8/2025 | |||
|Katie Schieffer | |||
| | |12/8/2025 | ||
| | |||
| | | | ||
|- | |- | ||
| Line 1,582: | Line 1,585: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |11/14/2025 | ||
| | |Katie Schieffer | ||
| | |11/14/2025 | ||
| | | | ||
|- | |- | ||
| Line 1,625: | Line 1,628: | ||
|Katie Schieffer | |Katie Schieffer | ||
|9/21/2025 | |9/21/2025 | ||
|12/ | |12/31/2025 | ||
| | |COMPLETE | ||
| | |11/14/2025 | ||
| | |Katie Schieffer | ||
| | |11/14/2025 | ||
| | | | ||
|- | |- | ||
| Line 1,773: | Line 1,776: | ||
|[[STBT5:Osteosarcoma|Osteosarcoma]] | |[[STBT5:Osteosarcoma|Osteosarcoma]] | ||
|Disease | |Disease | ||
|Fang Fang (trainee); Katie Schieffer (mentor) | |||
|11/19/2025 | |||
|2/15/2026 | |||
|PENDING | |||
| | | | ||
| | |Katie Schieffer | ||
| | | | ||
| | | | ||
| Line 1,853: | Line 1,856: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |11/14/2025 | ||
| | |Katie Schieffer | ||
| | |11/14/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]] | |[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]] | ||
| Line 1,961: | Line 1,964: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |11/14/2025 | ||
| | |Katie Schieffer | ||
| | |11/14/2025 | ||
| | |No genetic association, early genetic studies referenced | ||
|- | |- | ||
|[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]] | |[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]] | ||
| Line 1,983: | Line 1,986: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |11/14/2025 | ||
| | |Katie Schieffer | ||
| | |11/14/2025 | ||
| | |No genetic association | ||
|- | |- | ||
|[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]] | |[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]] | ||
| Line 1,994: | Line 1,997: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/22/2025 | ||
| | |Katie Schieffer | ||
| | |10/22/2025 | ||
| | | | ||
|- | |- | ||
| Line 2,025: | Line 2,028: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/21/2025 | ||
| | |Katie Schieffer | ||
| | |10/21/2025 | ||
| | | | ||
|- | |- | ||
| Line 2,036: | Line 2,039: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/21/2025 | ||
| | |Katie Schieffer | ||
| | |10/21/2025 | ||
| | | | ||
|- | |- | ||
| Line 2,062: | Line 2,065: | ||
| | | | ||
| | | | ||
| | |Refer to lipoma and hibernoma pages in STBT book | ||
|- | |- | ||
|[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]] | |[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]] | ||
| Line 2,073: | Line 2,076: | ||
| | | | ||
| | | | ||
| | |Refer to leiomyosarcoma page in STBT book | ||
|- | |- | ||
|[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]] | |[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]] | ||
| Line 2,091: | Line 2,094: | ||
|9/21/2025 | |9/21/2025 | ||
|12/21/2025 | |12/21/2025 | ||
| | |COMPLETE | ||
| | |10/21/2025 | ||
| | |Katie Schieffer | ||
| | |10/21/2025 | ||
| | | | ||
|- | |- | ||
| Line 2,106: | Line 2,109: | ||
| | | | ||
| | | | ||
| | |Refer to plasmacytoma page in heme book | ||
|- | |- | ||
|[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]] | |[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]] | ||
| Line 2,117: | Line 2,120: | ||
| | | | ||
| | | | ||
| | |Refer to heme book | ||
|- | |- | ||
|- | |- | ||
| Line 2,137: | Line 2,140: | ||
| | | | ||
| | | | ||
| | |Refer to heme book | ||
|- | |- | ||
|[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]] | |[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]] | ||
| Line 2,148: | Line 2,151: | ||
| | | | ||
| | | | ||
| | |Refer to heme book | ||
|- | |- | ||
|[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | |[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
| Line 2,159: | Line 2,162: | ||
| | | | ||
| | | | ||
| | |Refer to heme book | ||
|- | |- | ||
| | | | ||